Food & Drug Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Food & Drug Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Butler Hospital
ARICEPT may offer hope to those suffering from mild cognitive impairment
September 24th, 2004
Results of a new study published in Neurology show that ARICEPT (donepezil HCI), commonly used in the treatment of mild to moderate Alzheimer disease, may also offer hope to those suffering from mild cognitive impairment (MCI). This is the first published paper of a placebo-controlled trial with this class of drug to improve cognitive symptoms in MCI. MCI impacts more than 5 million Americans and the numbers are growing rapidly with the aging population. Patients in this study had the amnestic form of MCI. Patients with amnestic MCI have memory impairment out of proportion for their age but they do not meet the accepted criteria for...
Source: Food & Drug Law Weekly (2004-09-24)
|
